Reference : Risedronate reverses bone loss in postmenopausal women with low bone mass: results fr...
Scientific journals : Article
Human health sciences : General & internal medicine
http://hdl.handle.net/2268/125766
Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group.
English
Fogelman, I [> > > >]
Ribot, C [> > > >]
Smith, R [> > > >]
Ethgen, D [> > > >]
Sod, E [> > > >]
REGINSTER, Jean-Yves mailto [Centre Hospitalier Universitaire de Liège - CHU > > Médecine de l'appareil locomoteur]
2000
Journal of Clinical Endocrinology and Metabolism
Endocrine Society
85
5
1895-900
Yes (verified by ORBi)
International
0021-972X
Chevy Chase
MD
[en] Aged ; Bone Density/drug effects ; Calcium/therapeutic use ; Calcium Channel Blockers/adverse effects/therapeutic use ; Double-Blind Method ; Etidronic Acid/adverse effects/analogs & derivatives/therapeutic use ; Europe ; Female ; Femur ; Humans ; Lumbar Vertebrae ; Middle Aged ; Osteoporosis, Postmenopausal/drug therapy ; Placebos ; Time Factors
[en] Our objective was to investigate the efficacy and tolerability of risedronate in postmenopausal women with low bone mass. Women with a mean lumbar spine T-score of -2 or less (n = 543) received 24 months of placebo or risedronate (2.5 or 5 mg/day). All received calcium (1 g/day). The principal outcome measures were bone mineral density (BMD) at the lumbar spine, femoral neck, and femoral trochanter. At 24 months, lumbar spine BMD increased from baseline by 4% with 5 mg risedronate and 1.4% in the 2.5-mg group, compared with no change with placebo. Efficacy was similar in women who were less than 5 yr and more than 5 yr postmenopausal. At 24 months, risedronate (5 mg) had also increased BMD at the femoral neck and trochanter, whereas BMD decreased in the placebo group. BMD increases were seen at all three sites with risedronate (5 mg) after only 6 months of therapy. Risedronate was well tolerated; upper gastrointestinal adverse events were similar to placebo. We conclude that risedronate (5 mg) increases BMD rapidly and effectively and is well tolerated in postmenopausal women with low bone mass, regardless of time since menopause.
http://hdl.handle.net/2268/125766

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Risedronate reverses bone loss in postmenopausal women with low bone mass.pdfPublisher postprint667.15 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.